Inicio > BIGG > Resultado de la búsqueda

    Resultados: 2

    Canadian Cardiovascular Society Guidelines for Evaluation and Management of Cardiovascular Complications of Cancer Therapy

    Dent, S; Brezden-Masley, C; Clarke, B; Davis, MK; Jassal, DS; Johnson, C; Lemieux, J; Paterson, I; Sebag, IA; Simmons, C; Sulpher, J; Thain, K; Thavendiranathan, P; Wentzell, JR; Wurtele, N; Côté, MA; Fine, NM; Haddad, H; Hayley, BD; Hopkins, S; Joy, AA; Rayson, D; Stadnick, E; Straatman, L; Virani, SA.
    Can. j. cardiol; 32 (7), 2016
    Modern treatment strategies have led to improvements in cancer survival, however, these gains might be offset by the potential negative effect of cancer therapy on cardiovascular health. Cardiotoxicity is now recognized as a leading cause of long-term morbidity and mortality among cancer survivors. This ...
    Antineoplásicos, Biomarcadores, Cardiotónicos, Cardiotoxinas, Troponina T, Péptido Natriurético Encefálico, Proteína C-Reactiva, Antineoplásicos/efectos adversos, Arritmias Cardíacas, Cardiotoxicidad, Trombosis Coronaria, Diagnóstico Precoz, Ecocardiografía Tridimensional, Hipertensión/terapia, Imagen por Resonancia Cinemagnética, Isquemia Miocárdica, Neoplasias/terapia, Prevención Primaria, Radioterapia, Factores de Riesgo, Disfunción Ventricular Izquierda, Cardiotoxicidad/diagnóstico, Cardiotoxinas/efectos adversos, Radioterapia/efectos adversos
    Texto completo

    SIE, SIES, GITMO revised guidelines for the management offollicular lymphoma

    Zinzani, Pier Luigi; Marchetti, Monia; Billio, Atto; Barosi, Giovanni; Carella, Angelo Michele; Lazzarino, Mario; Martelli, Maurizio; Rambaldi, Alessandro; Rigacci, Luigi; Tarella, Corrado; Vitolo, Umberto; Tura, Sante.
    Am. j. hematol; 90 (1), 2005
    By using the GRADE system, we updated the guidelines for management of follicular cell lymphoma issuedin 2006 from SIE, SIES, and GITMO group. We confirmed our recommendation to frontline chemoimmuno-therapy in patients with Stage III–IV disease and/or high tumor burden. Maintenance rituximab was alsor...
    Anticuerpos Monoclonales, Anticuerpos, Anticuerpos Monoclonales de Origen Murino/uso terapéutico, Antineoplásicos, Esquema de Medicación, Trasplante de Células Madre Hematopoyéticas, Linfoma Folicular/patología, Linfoma/terapia, Estadificación de Neoplasias, Rituximab, Factores de Tiempo
    Texto completo